Filing Flows › Bionano Genomics (BNGO) › Q4 2024
Bionano Genomics (BNGO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Bionano Genomics (BNGO) reported revenue of $8.2M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and +34% from the quarter before. Operating margin was -146.3%, net loss $20.1M (246.5% of revenue).
Bionano Genomics, Q4 2024: revenue $8.2M (-24% year over year), operating margin -146.3%, net loss $20.1M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.2M | +34% | -24% |
| Operating profit | −$11.9M | — | — |
| Net earnings | −$20.1M | — | — |
| Operating cash flow | −$6.5M | — | — |
What changed
Revenue was $8.2M in Q4 2024, down 24% year over year and up 34% from the previous quarter. Product revenue was the largest line at 94% of revenue.
Operating costs exceeded revenue by $11.9M, an operating margin of -146.3%. Total costs fell 44% while revenue fell 24%. The quarter ended with a net loss of $20.1M, narrower than the previous quarter's $44.2M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $2.4M of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $9.3M.
Questions
What was Bionano Genomics' revenue in the fourth quarter 2024?
Bionano Genomics (BNGO) reported revenue of $8.2M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and +34% from the quarter before.
Was Bionano Genomics profitable in the fourth quarter 2024?
Operating loss was $11.9M (-146.3% of revenue) and net loss $20.1M.
Source: Bionano Genomics 10-K on SEC EDGAR.